I wish to thank Ric Price and colleagues1 for highlighting the under-studied chloroquine resistance in Plasmodium vivax in their systematic review and meta-analysis. However, I would question their study inclusion criteria: the primary outcome was “the risk of recurrent P vivax parasitaemia at day 28” when table 1 lists four studies with follow-up periods of less than 27 days. I would also suggest that it seems a shame that two author-reviewers, independently, did not extract and analyse the studies and data for inclusion, as seems standard practice for good systematic reviews. 2 Lastly, although the paper underlines the extent and importance of chloroquine-resistant P vivax, I am none the wiser on what management I should offer in practice to patients from different areas given the prevalence of resistance. I declare no competing interests.